

Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis

NCT07491016

Status RECRUITING
Sponsor Zhejiang Provincial People's Hospital
Enrollment 30 participants

Key Eligibility Criteria

Inclusion (4)

- Age 18-85 years
- Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria
- The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients
- Voluntarily provided written informed consent

Exclusion (8)

- Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs)
- Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis)
- History of allergy/hypersensitivity to the study medications (Telitacicept or Tofacitinib)
- Active tuberculosis or active infectious diseases requiring systemic treatment
- Pregnancy, lactation, or refusal to use contraception during the study
- ... and 3 more (see full listing online)

Locations (1 total)

Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China